Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Currently there is no oral argument listed for Amarin v. Hikma in an updated CAFC February calendar or in a new March calendar. There could be further updates or news of a confidential settlement. OTOH, the parties may still be in line for an argument slot on a first come basis after submission of the necessary paperwork.
NVO buys CTLT to increase capacity for production of weight loss drug Wegovy. Purchase price = $11.5 Billion cash.
Per TDA, VKTX will report/discuss 4th quarter and year-end 2023 financial results on February 7 at 4:30 pm. A general corporate update will also be discussed.
Was the AMRN CFO form 4 filing the only one? It looked like 3 separate filings by different people to me.
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
I read your quote. Dr Gottlieb was on CNBC-TV at 2:30 pm today, discussing LLY and NVO pipelines and additional advantages/diseases to be obtained from treatments using respective weight loss drugs. Earlier, BMY/MRK patent cliffs were featured, with additional M/A activity discussed to diversify respective pipelines to treat additional diseases.
A good match between your quote and above discussion, IMO. Additional patent protection and reasonable M/A cost favor AMRN.
It’s about time to check the CAFC calendar to see whether the February oral argument calendar has been updated and the March oral argument calendar has been published.
Do we know what TEVA has done with that rather large amount of EPA that was delivered to Vancouver or Seattle ports some weeks ago? I believe I asked #sleven if he could trace where it went; I recall he could not.
Thermofisher CEO will be on CNBC-TV later today. Maybe some insights there.
Zimmer and Stryker are doing more surgical procedures that usually require pain relief and inflammation reducing meds. Has CDMO been in that field? How about bacteria and virus fighting meds, newly discovered or conventional?
Look at a 5-year chart. AMRN was in the $18-20 range. Then consider all the approvals since, not extant when Dr. Bhatt released preliminary results at AHA in Chicago. I agree with others who are looking for a $18-20 buyout. A petition to the FDA Commissioner, a cardiologist, just might force generics to make a label change: “This product is not approved for use in treating cardiovascular diseases.” Stay tuned.
Does that conform with bfiest’s links that I thought said Avid sold and the respective funds acquired. Maybe a mistake if the 2 funds did reduce their CDMO positions.
Thanks for those links from State Street and Altravue. Substantial purchases by each fund. At $6.94, it looks like our 55,000 shares in 2 accounts have regained profitability. We missed the grand opening of the new facilities this past week.
Note appointment of Dr. V. Ramjee, a cardiovascular expert, as Strategic Advisor to CDIO. Background: Mount Sinai School of Medicine, Emory and U. Pennsylvania Hospitals. Does Amarin and its cardiovascular experts have previous/current contact with Dr. Ramjee that could be useful in increasing Vascepa use in the United States? I am still thinking of a collaboration between Amarin(Vascepa treatment) and CDIO(CVD diagnostic)
Amarin requested a jury trial when it filed its complaint alleging patent infringement by Hikma in Delaware in 2020. A motion to dismiss filed by Hikma was granted by Judge Andrews, now on appeal to CAFC with no time yet set for oral arguments. You appear to be unaware of that case.
Kiwi, there are 4–6 “generic Vs”. Are you stating that one of the “new” generic Vs is actually a rebottled/relabeled Brand Vascepa? Do you, or anyone else, have proof of that position? It sounds like a good way of getting rid of older, dated, expiring inventory. What FDA regulations permit that maneuver?
DOI: 10.1056/NEJMoa230836
Traverse Clinical Trial, NCT03518034, AbbVie
N Engl J Med 2024; 203-11 and 267
There were a lot of preliminary votes by AHA society experts and members in 2019 and later. Preliminary votes are nice but don’t count. Does your visual graph now reflect actual society votes as of 2022-2023?
If I may interrupt, it appears to be a committee of experts at AHA staffed by experts who are either not sufficiently expert or don’t meet often enough to vote Vascepa into the appropriate guidelines. ADA was far better in late 2019. As a T1 diabetic, I visited ADA HQ in Alexandria, Va. I was told by the executive secretary that Vascepa had already been placed in ADA guidelines. BTW, my PCP is not a cardiologist but is a former NIH research M.D. who had no difficulty in prescribing Vascepa for me in late 2012. I was his first patient for whom he prescribed Vascepa. Recently he told me that he now has more patients on V than the 20 he estimated a few years ago.My co-pay continues to be $9 or $15 for a 3-month supply of Vascepa.
We have 500 shares in each of 2 accounts. Both are profitable, entry ~ $4 in the IRA, LTCG. XBI, IBB negative today. No worries, but Fed bears watching, eh?
Off > $3 from your post 2 weeks later. Trading at $7.12 at 1:50 pm today. News? None that I see.
HALO turned positive mid-day. Anybody listen to their conference call this morning? Takeda received FDA approval for its Enhanze-enhanced therapy AH yesterday. This should help CDMO.
I had bought 2000 AMRN, 1000 PHUN, 200 ACXP in a new joint account that I had established last year with the IRA RMD cash derived from PFE/SGEN merger.
Avid Bioservices(CDMO) has already invested heavily, both in its manufacturing plants in Tustin and a new virus/gene plant near John Wayne airport in California. HALO is a prime customer; CDMO supplies bulk material to HALO for use in its ENHANZE device that enables subcutaneous injection of products produced by Roche in Europe and JNJ.
MLK holiday. Markets closed.
The CAFC revised/updated its calendar of case arguments today. I found no Amarin v. Hikma listed for January or February 2024.
Your message is incomplete because it does not tell the countries that Vascepa or Vazkepa treatment is available to treat, or reduce the risk from, heart disease. Include the prescription criteria once diagnosis of CVD is made.
Methinks it is no buying back in 1st quarter. Shareholders will have a chance to vote to approve buyback early in April at special meeting in early April, according to Amarin PR. Or is the company first quarter one that starts in April?
We sold 40 of our 800 shares we bought at split-adjusted $4.31 more than a decade ago to get our up-money back. All $$profit now—about a 12,0490% return on basis.
Did you buy or sell those Puts?
Have ABBV found a way to make testosterone patches so they do not itch? My PCP says that his patients discontinue patches because of the itch so he prescribes creams.
News that NVS is in talks to buy CYTK for its heart drug hit the media wires about 1 pm today, per CNBC-TV. Deal could be finalized this week. Does this news negate opinions expressed by many of us that NVS intends to acquire AMRN? Stay tuned.
With a number of investments in our portfolio( e.g., JNJ, GILD, MRK, AMD, BA, NVDA), I saw their news releases on CNBC-TV this morning before I found time to investigate their websites or read any PR that might become available tomorrow. Thanks for the info about AMRN IR that I had not read or heard.
You might ask Amarin IR whether Amarin intends to release the Medicare news on its website to news media in North America. Let us know about a response.
There are at least 16 AI-directed cardiology websites with algorithms that will alert hospitals and cardiology staff wrt cardiology diagnostic and treatment news, per Dr. Topol of Scripps as I posted earlier. Do you doubt that the Medicare news placed on the Amarin website over the past weekend about Vascepa has already been incorporated into those algorithms and is now available to hospitals and cardiologists faced with patients in need of reduction of reducing risk from forms of cardiovascular disease? My own PCP is always concerned about whether my insurance plan will cover or reduce co-pay cost of medications he prescribes.
Note the Medicare and Medicare Advantage information placed on Amarin’s website over the weekend. Vascepa is placed in an Exclusive or Preferred position by many insurance plans as the medication to use to reduce the risks ensuing from various forms of cardiovascular disease. AI will make that information readily available to hospitals and staff cardiologists worldwide.
An idea, Capt: 1) We know PFE is selling Vascepa to general M.D. practitioners in Canada. 2) We know LLY has adopted a policy of selling/shipping its weight loss drug to consumers at their home/location on receipt of an M.D prescription. 3) I know that CDIO announced yesterday a new business model platform, HeartRisk, whereby employers may contract with CDIO to screen their employees (in HIPPA protected mode) for CVD risk, making use of the FDA C-mark it received for its AI-driven diagnostic test of employee CVD risk. See CDIO PR yesterday for details of its program, effective 2/4/2024, for reducing employer healthcare CVD healthcare costs of $363 billion annually(UNH data).
Will any of AMRN, PFE, NVS adopt LLY’s program of selling meds to consumers at home or office locations?
Ouch, had no stop orders placed on either 3500 shares CORT or 2500 shares AVXL. Both are coming back a little today. Lucky that my basis is $1.34 in CORT and $1.80 in AVXL.
I recall Carl Icahn got a $10 higher bid from LLY for IMCL shares more than a decade ago. AMLN had an auction buyout process that was won by BMY/AZN in a joint bid against other bidders. Is there a similar activist investor/BOD member or other shareholder extant here? So far I have seen no 6-month negotiation process like occurred when BMY acquired MEDX.
OT to Kiwi—did you see where CDIO received a reimbursement code for its cardiology disease diagnostic test algorithm from AMA yesterday, per PRs yesterday and today? I have sold none of the 10k shares purchased in early November—fast 600% return so far.
https://alz-journals.onlinelibrary.wiley.com/hub/journal/15525279/homepage/productinformation
Open access of Alz. journal tomorrow, 01/01/2024....link inoperative already?
Another interesting link, cardiologist Topol of Scripps, on TEDTALK, 12/2023:
https://www.ted.com/talks/eric_topol_can_ai_catch_what_doctors_miss
Machine learning---look what can be diagnosed from an eye-exam. 13' of slides and readable transcript.